BioLamina
BioLamina is a Swedish biotechnology company that develops and sells full-length human recombinant laminin proteins (Biolaminin®) and recombinant spider silk scaffolds for primary cell, stem cell, and iPSC-derived cell culture, serving academic researchers, biotech, and pharmaceutical organizations globally across research and clinical-grade applications.
- Company typePrivate
- Founded2009
- HeadquartersSundbyberg, Sweden
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioLamina does
BioLamina AB is a privately held Swedish biotechnology company founded in 2009 in Sundbyberg, Sweden, that develops and manufactures full-length human recombinant laminin proteins marketed under the Biolaminin® brand. Its core products are chemically defined, animal-origin-free extracellular matrix substrates used to culture primary cells, pluripotent stem cells, and iPSC-derived cell types across 2D and 3D formats. The portfolio spans three regulatory tiers: LN (research grade), MX (translational research grade), and CTG (Cell Therapy Grade, with quality documentation suitable for ATMP manufacturing); product breadth covers at least ten tissue-specific laminin isoforms (e.g., LN521 for PSCs, LN111 for hepatocytes, LN211/221 for muscle/cardiac, LN332 for epithelial, LN411 for pancreas/vascular, LN421 for endothelial/kidney). The company also sells Biosilk, a recombinant spider silk 3D scaffold that can be biofunctionalized with Biolaminin isoforms for organoid culture. Scientific credibility is anchored in 428+ peer-reviewed publications and 31+ clinical journeys acknowledged by regulatory agencies including the FDA.
BioLamina operates a hybrid go-to-market combining self-service e-commerce for research-grade SKUs, a direct sales team for enterprise and large-quantity orders (including a wholly owned US subsidiary, BioLamina Inc., in Cambridge, MA), and an actively expanding global distributor network. Pricing is quote-based for large orders; shipments are ExWorks (Incoterms 2020). The company is funded by a €17M equity round in September 2023 led by Lauxera Capital Partners (with Bure Equity, Northislet, and founders) and a €20M EIB venture debt facility in April 2026; ownership is concentrated with Bure Growth (51.7%), Lauxera (16.2%), the Tryggvason family (15.3%), and Northislet (14.3%). Approximately 100 employees as of September 2025 serve academic researchers, biotech and cell therapy developers, and pharmaceutical organizations globally, with target indications including type 1 diabetes, Parkinson's disease, heart failure, acute liver failure, and cancer.
The business model is a one-time unit-pricing sale of consumable reagents, supplemented by grant-funded collaborative research (more than one-third of product development is publicly funded, with BioLamina acting as lead project manager on half of these collaborations). Recent strategic moves include the CEO transition to Klaus Langhoff-Roos (August 2024) and CTO Brian Hawkins (March 2025), alongside three new channel and co-development partnerships in late 2025 and 2026 (Cell X Technologies, Pluristyx, Cytochroma) that embed Biolaminin reagents into automated iPSC manufacturing workflows and downstream drug-discovery cell products.
BioLamina firmographics
Firmographics- Name
- BioLamina
- Legal name
- BioLamina AB
- Website
- https://biolamina.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- BioLamina is a Swedish biotechnology company that develops and sells full-length human recombinant laminin proteins (Biolaminin®) and recombinant spider silk scaffolds for primary cell, stem cell, and iPSC-derived cell culture, serving academic researchers, biotech, and pharmaceutical organizations globally across research and clinical-grade applications.
- Ownership category
- akta.pro rank
BioLamina industry classification
Industry- Product category
- Cell Culture Reagents
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)
- akta.pro secondary industries
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), 3D Bioprinting & Biofabrication (HLAAAGAC), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
Keywords
Where BioLamina is headquartered
LocationHeadquarters
- HQ city
- Sundbyberg
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
BioLamina business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Biolaminin product sales: Sale of full-length human recombinant laminin proteins (Biolaminin®) across three product grades: LN (research grade), MX (translational research grade), and CTG (cell therapy grade). Products are sold via e-commerce webstore and direct sales. Pricing is quote-based for large orders.
- Biosilk product sales: Sale of Biosilk and Biosilk 521 recombinant 3D culture scaffolds for organoid and 3D cell culture applications.
- Collaborative research and grant funding: More than one-third of product development projects are publicly funded via grants. BioLamina serves as lead project manager for half of these collaborations. Grants support collaborative projects with academic and industry partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Biolaminin LN (research grade) — full-length human recombinant laminin for basic research |
| Unit Pricing | Pay-as-you-go | Biolaminin MX (translational research grade) — for research aiming at clinical applications |
| Unit Pricing | Pay-as-you-go | Biolaminin CTG (cell therapy grade) — for clinical applications |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels9 records
BioLamina product offering
Product offeringCore offering
BioLamina develops and manufactures full-length human recombinant laminin proteins (Biolaminin®) for 2D and 3D cell culture applications, offering 10+ tissue-specific isoforms across research (LN), translational research (MX), and Cell Therapy Grade (CTG) tiers for stem cell expansion, lineage differentiation, and GMP-compliant cell therapy manufacturing. The company also produces Biosilk, a recombinant spider silk scaffold for organoid and 3D culture, with Biosilk 521 combining the scaffold with Biolaminin 521 for pluripotent stem cell niches.
Product overview
BioLamina offers an expansive portfolio of full-length human recombinant laminin proteins under the Biolaminin® brand, designed for a variety of cell culture applications in both 2D and 3D formats. The product portfolio is organized across three tiers: LN (research grade) for basic research, MX (translational research grade) for research progressing toward clinical applications, and CTG (Cell Therapy Grade) for clinical use. Key products include Biolaminin 521 (LN521, MX521, CT521) for pluripotent stem cells, alongside tissue-specific isoforms such as LN111 (liver/epithelial), LN211/LN221 (muscle/cardiac), LN332 (epithelial), LN411 (pancreas/vascular/hematopoietic), LN421 (endothelial/kidney), and LN511 (mouse ESCs). The company also offers Biosilk and Biosilk 521 as 3D culture substrates—recombinant spider silk matrices that can be functionalized with Biolaminin isoforms for organoid formation. Biolaminin products are chemically defined, animal-origin-free, and support applications ranging from basic research to GMP-compliant cell therapy manufacturing across major regulatory jurisdictions.
Differentiator
Problem solved
Functional benefit
Brands
- Biolaminin: Full-length human recombinant laminin protein product line for cell culture applications, including research grade (LN), translational research grade (MX), and cell therapy grade (CTG) products.
- Biosilk
Products and services
- Biolaminin 521 LN (LN521) Full-length human recombinant laminin-521 substrate for pluripotent stem cells (ESCs and iPSCs). The natural laminin for human PSCs, supporting self-renewal under defined, animal-origin-free conditions and enabling single-cell passaging without apoptosis inhibitors such as ROCK inhibitor. Research-grade (LN) product.
- Biolaminin 521 MX (MX521) Full-length laminin-521 substrate designed for research aiming for clinical applications. Translational research grade (MX) supporting large-scale production and regulatory compliance. Chemically defined, batch-to-batch consistent, and animal-origin-free to the secondary level.
- Biolaminin 521 CTG (CT521) Full-length laminin-521 substrate designed for clinical applications. Cell Therapy Grade (CTG) with the most extensive quality control and regulatory compliance for GMP-compliant cell therapy production. Chemically defined, batch-to-batch consistent, and animal-origin-free to the secondary level with comprehensive quality documentation including Certificate of Analysis.
- Biolaminin 511 LN (LN511) Full-length human recombinant laminin-511. The natural laminin for mouse embryonic stem cells, supporting sustained pluripotency without LIF. Also efficiently supports various human cell types including neural and hepatic lineages. Research-grade (LN) product.
- Biolaminin 111 LN (LN111) Full-length human recombinant laminin-111, an essential extracellular matrix component for many cell types in vivo. Particularly useful for liver cells and various epithelial cell types. Research-grade (LN) product.
- Biolaminin 121 LN (LN121) Full-length human laminin-121 protein used as a general attachment protein for many cell types in culture. Research-grade (LN) product.
- Biolaminin 211 LN (LN211) Full-length human recombinant laminin-211 supporting growth, survival, and differentiation of tissue-specific cell types including motor neurons, cardiac cells, and skeletal muscle cells. Research-grade (LN) product.
- Biolaminin 221 LN (LN221) Full-length human recombinant laminin-221 supporting growth, survival, and differentiation of tissue-specific cell types including cardiac cells and skeletal muscle cells. Research-grade (LN) product.
- Biolaminin 332 LN (LN332) Full-length human recombinant laminin-332 supporting cells in epithelial basement membranes located in several tissues. Research-grade (LN) product.
- Biolaminin 411 LN (LN411) Full-length human recombinant laminin-411 supporting diverse tissue cell types such as cells from the pancreas, vascular, immune, nervous, and hematopoietic systems. Research-grade (LN) product.
- Biolaminin 421 LN (LN421) Full-length human recombinant laminin-421 supporting several tissue-specific cell types such as endothelial and kidney cells. Research-grade (LN) product.
- Biosilk Recombinant spider silk protein that forms a fibrous 3D network mimicking natural extracellular matrices. Provides a versatile scaffold for 3D cell culture and tissue engineering with excellent biocompatibility and biodegradability. Can be biofunctionalized with tissue-specific Biolaminin isoforms for organoid formation.
- Biosilk 521 Recombinant 3D culture matrix biofunctionalized with Biolaminin 521 at 9 µg/mL concentration. Creates stem cell-relevant niches for pluripotent stem cells (PSCs) and progenitors in a 3D culture format for organoid and stem cell expansion applications.
Quantifiable outcome
- 2–7x more pluripotent stem cells over 10 days compared to fragmented laminins; cells survive single-cell passaging without ROCK inhibitor
- +5 more outcomes
Companies that use BioLamina
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
BioLamina technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature6 records
BioLamina partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- CytochromacoreStrategic collaboration to incorporate BioLamina's full-length human recombinant laminin 521 into Cytochroma's iPSC-derived cell product offerings (hepatocytes and cardiomyocytes) for drug discovery and disease modelling. Cytochroma has used Biolaminin since 2017, making it one of BioLamina's longest-standing partners. The partnership aligns with FDA Modernization Act 2.0 and supports generation, recovery, and expansion of iPSC-derived cells. Joint marketing activities, scientific engagement, and conference collaborations planned throughout 2026.
- Organoid COMMONS (led by Pluristyx)minorPluristyx announced the Organoid COMMONS consortium aimed at establishing global standards for organoid development to support drug discovery and regulatory acceptance. The initiative involves ten industry partners seeking to replace traditional animal testing with human-relevant organoid models. While BioLamina is not explicitly named as a consortium partner in the source material, Pluristyx is a strategic partner of BioLamina.
- Cell X TechnologiescoreCollaboration to integrate BioLamina's defined laminin reagents (Biolaminin® LN521 and LN511, including GMP-compatible formulations) with Cell X's Celligent™ automation platform. Partnership aims to reduce operator-dependent variability and enhance reproducibility in advanced therapy manufacturing. Combines walk-away automation and imaging with high-quality laminin reagents to deliver scalable, GMP-compliant workflows for next-generation iPSC-based cell therapies.
- PluristyxcoreStrategic partnership to accelerate development of stem cell-based therapies. BioLamina products (including Biolaminin 521 LN) are integrated into Pluristyx's product platform. BioLamina's products were also featured in Pluristyx's PluriKit launched December 2024. The partnership combines Pluristyx's gene-modified iPSC platform with BioLamina's laminin reagents for next-generation cell therapy manufacturing.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
BioLamina competitors and assessment
Company assessmentBroad incumbents
- Corning Incorporated: Corning Life Sciences is the dominant incumbent in cell culture substrates via Matrigel (its primary competing ECM product) and a broad portfolio of media, vessels, and surface treatments. Comparable as the incumbent alternative to BioLamina's recombinant laminins, particularly in research-grade stem cell culture.
- Thermo Fisher Scientific: Thermo Fisher offers CellMatrix, vitronectin-based substrates (e.g., rhVTN-N), and the full Gibco cell culture portfolio. Comparable as a broad incumbent that bundles substrates with media, cells, and instruments—directly competing with BioLamina's research and translational product tiers.
- Merck KGaA (Millipore Sigma): Millipore Sigma supplies human recombinant laminins (fragmented forms such as LM521), cell culture media, and GMP-grade manufacturing reagents. Comparable as an incumbent with overlapping laminin offerings and a much broader portfolio that competes head-to-head with BioLamina in both research and clinical-grade applications.
- Bio-Techne: Bio-Techne (R&D Systems, Tocris, ProteinSimple) supplies recombinant proteins, including laminins, as well as media, small molecules, and analytical tools for stem cell and cell therapy workflows. Comparable as a direct competitor in research-grade cell culture reagents with established distribution in academic and biotech channels.
- FUJIFILM Irvine Scientific: FUJIFILM Irvine Scientific supplies defined cell culture media and reagents for cell therapy manufacturing (including PRIME-XV and related lines) and competes directly with Biolaminin CTG products in GMP-compatible stem cell workflows. Comparable as an incumbent in clinical-grade cell therapy manufacturing consumables.
- Lonza Group: Lonza offers cell therapy manufacturing services, media (e.g., TheraPEAK, L7 media), and a range of ancillary materials for iPSC and cell therapy workflows. Comparable as an incumbent in clinical-grade cell therapy reagents and CDMO services, often partnered with or competing against BioLamina's CTG products.
Direct peers
- STEMCELL Technologies: STEMCELL Technologies is a leading specialized supplier of cell culture media, substrates, and tools for stem cell, immunology, and cell therapy research. Directly comparable as a specialized cell culture reagents vendor with overlapping customer base (academic researchers, biotech, and cell therapy developers) and similar product-led growth motion.
- CellGenix: CellGenix is a specialized supplier of GMP-grade raw materials and ancillary materials for cell therapy, gene therapy, and tissue engineering manufacturing. Directly comparable as a niche GMP-focused competitor to BioLamina's CTG laminin products in cell therapy manufacturing supply chains.
- Pluristyx:
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
BioLamina social profiles
Digital presenceBioLamina financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioLamina leadership team
Management profileNumber of profiles
Profiles9 records
BioLamina subsidiaries and ownership
Company hierarchySubsidiaries1 record
BioLamina funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioLamina M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioLamina
What does BioLamina do?
BioLamina develops and manufactures full-length human recombinant laminin proteins (Biolaminin®) for 2D and 3D cell culture applications, offering 10+ tissue-specific isoforms across research (LN), translational research (MX), and Cell Therapy Grade (CTG) tiers for stem cell expansion, lineage differentiation, and GMP-compliant cell therapy manufacturing. The company also produces Biosilk, a recombinant spider silk scaffold for organoid and 3D culture, with Biosilk 521 combining the scaffold with Biolaminin 521 for pluripotent stem cell niches.
Is BioLamina a public or private company?
BioLamina is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioLamina founded?
BioLamina was founded in 2009. It employs 51 to 100 people.
Where is BioLamina based?
BioLamina is headquartered in Sundbyberg, Sweden, in the Europe region.
How does BioLamina make money?
Three revenue lines are on record. Biolaminin product sales are the primary driver. The others are biosilk product sales and collaborative research and grant funding.
Who are BioLamina's main competitors?
Broad incumbents on record are Corning Incorporated, Thermo Fisher Scientific, Merck KGaA (Millipore Sigma), Bio-Techne, FUJIFILM Irvine Scientific and Lonza Group. Direct peers are STEMCELL Technologies, CellGenix and Pluristyx.
Does BioLamina have an API?
No public API is recorded for BioLamina.
What industry is BioLamina in?
BioLamina's product category is Cell Culture Reagents. Its primary akta.pro industry code is HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.